DEA Announces Important Change to Registration Requirement

For a full copy of the DEA letter, click here.

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.”

All DEA registrants should be aware of the following:

• A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
• Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
• There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
• The Act does not impact existing state laws or regulations that may be applicable.

CSAM Members need to know that currently, California does not have any additional regulations above the federal level.

The Act also introduced new training requirements for all prescribers. These requirements will not go into effect until June 21, 2023. CSAM is monitoring the information as it is released by DEA and SAMHSA and will provide education updates accordingly.

For targeted education on Opioid Use Disorder, visit CSAM’s Education Center, which offers on-demand activities, including:

• Treating Opioid Use Disorder and Managing Chronic Pain in Today’s Epidemic of Overdose Deaths

• 2022 State of the Art Conference, which includes sessions on:
• Opioids
• Buprenorphine
• Compliance Information

Please note that if you do not have an existing CSAM Education Center Account,

you will have to register for an account here prior to purchasing the course.

This is a different account from the CSAM home page account!